NASDAQ:IMTX
immatics biotechnologies GmbH Stock News
$10.96
+0.150 (+1.39%)
At Close: May 17, 2024
Immatics Announces Second Quarter 2021 Financial Results and Provides Business Update
07:00am, Tuesday, 10'th Aug 2021
Tuebingen, Germany and Houston, TX, August 10, 2021 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redir
BioCopy, Immatics Team Up For Characterization Of TCR-Peptide-HLA Interactions
11:27am, Wednesday, 07'th Jul 2021
Switzerland-based BioCopy AG has collaborated with Immatics N.V. (NASDAQ: IMTX) to characterize T cell receptors (TCRs).
BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor - peptide-HLA interactions
03:00am, Wednesday, 07'th Jul 2021
BASEL, Switzerland and TÜBINGEN, Germany, July 7, 2021 /PRNewswire/ -- BioCopy AG announces a collaboration with Immatics N.V. (NASDAQ: IMTX) "Immatics" in the field of characterization of T cell rec
Immatics Announces First Quarter 2021 Financial Results and Business Update
07:00am, Tuesday, 18'th May 2021
Tuebingen , Germany and Houston, TX , May 18 , 20 2 1 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell red
Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRAME
07:00am, Tuesday, 11'th May 2021Immunocore: 'Off-The-Shelf' T Cell Therapy
11:13am, Monday, 12'th Apr 2021
Immunocore: 'Off-The-Shelf' T Cell Therapy
IMTX Stock Price Increased Over 5% Pre-Market: Why It Happened
09:15am, Tuesday, 30'th Mar 2021
The stock price of Immatics N.V. (NASDAQ: IMTX) increased by over 5% pre-market.
Immatics Announces Full Year 2020 Financial Results and Corporate Update
07:00am, Tuesday, 30'th Mar 2021
Tuebingen, Germany and Houston, TX, March 30, 2021 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redire
IMTX Stock Price Increased Over 58% Intraday: Why It Happened
02:48pm, Wednesday, 17'th Mar 2021
The stock price of Immatics N.V. (NASDAQ: IMTX) increased by over 58% during intraday trading.
IMTX Stock: Why Immatics Shares Are Rocketing Higher Today
12:55pm, Wednesday, 17'th Mar 2021
A press release from the company is showing promise in shrinking cancerous tumors. The discoveries are leading to a rise in IMTX stock.
Immatics Stock Trading Higher As Cell Therapy Program Shows Anti-Tumor Activities In Pretreated Cancer Patients
11:40am, Wednesday, 17'th Mar 2021
Immatics NV (NASDAQ: IMTX) has announced a clinical data update from the dose-escalation cohorts of the ongoing Phase 1 trial evaluating its ACTengine product candidates IMA201, IMA202, and IMA203.
Why Bluebird Bio, Onconova, FSD Pharma, Immatics Are Moving Wednesday
11:23am, Wednesday, 17'th Mar 2021
bluebird bio, Inc. (NASDAQ: BLUE), Onconova Therapeutics, Inc. (NASDAQ: ONTX), FSD Pharma Inc. (NASDAQ: HUGE) and Immatics N.V. (NASDAQ: IMTX) are among the biggest biopharma movers in Wednesday's ses
Immatics Announces European Clinical Expansion of its Adoptive Cell Therapy Programs
11:00am, Tuesday, 18'th Aug 2020
Tuebingen, Germany and Houston, Texas, Aug. 18, 2020 (GLOBE NEWSWIRE) -- * First patient has been treated in Germany in Immatics’ ACTengine® IMA202-101 trial * German regulatory agency, Paul-Ehr
Immatics Extends Cell Therapy Manufacturing Collaboration with UTHealth
11:00am, Thursday, 06'th Aug 2020
Houston, Texas, Aug. 06, 2020 (GLOBE NEWSWIRE) -- * Extension of collaboration between UTHealth and Immatics until end of 2024 providing Immatics exclusive access to state-of-the art cGMP manufact
Bill Ackman's Pershing Square Tontine Joins A Long List Of 2020 SPAC Milestones
10:19am, Friday, 24'th Jul 2020
Pershing Square Tontine Holdings raised $4 billion and traded up 6.5% yesterday, becoming the largest Special Purpose Acquisition Company (SPAC) ever to go public.
